Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
about
Fecal microbiota transplantation for the treatment of Clostridium difficile infectionWhat is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?Clostridium difficile Infection in Special High-Risk PopulationsThe potential for emerging therapeutic options for Clostridium difficile infectionRandomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infectionMicrobiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during Clostridium difficile Infection.Procalcitonin levels associate with severity of Clostridium difficile infectionDerivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy.Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile InfectionFecal microbiota transplantation for the management of Clostridium difficile infectionComparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model.Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection--an observational cohort study.Clostridium difficile drug pipeline: challenges in discovery and development of new agentsDiscovery and development of surotomycin for the treatment of Clostridium difficile.Fidaxomicin--the new drug for Clostridium difficile infectionCost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harmAssociation of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin ProductionThe Daniel K. Inouye College of Pharmacy Scripts: Updates on Clostridium difficile Infection: Advances in Laboratory Testing to Aid Diagnosis and Treatment.Fecal transplant in refractory Clostridium difficile colitis.Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel DiseaseElevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrheaA cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in GermanyDiarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cellsFidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.Clinical update for the diagnosis and treatment of Clostridium difficile infection.Variations in virulence and molecular biology among emerging strains of Clostridium difficile.Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Opportunistic infections due to inflammatory bowel disease therapy.Fidaxomicin: a review of its use in patients with Clostridium difficile infection.Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.Clostridium difficile infection in patients with liver disease: a review.How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD.Cadazolid for the treatment of Clostridium difficile.A Review of Management of Clostridium difficile Infection: Primary and Recurrence.Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
P2860
Q26783516-8881AA63-49AD-417E-9D91-89BBDB278416Q27687191-E21587CF-BE61-4C92-BAA0-3CE115F93F6AQ28069414-7967C34B-C464-412A-A255-B7A6A1B66014Q28082059-493A777F-A0BF-4658-BF15-1405819579BDQ28258066-C294CCD1-7908-4FC0-BA9C-20A8C292FC3BQ30276498-7DFD18B7-2B00-4262-8029-BBD4CEF7F3CDQ34625689-41525CBC-22CA-4731-B06A-912FE9DD9F43Q34636539-F5B21E03-AC7C-4510-B303-A925B7556937Q34726133-F8B1D1CD-164C-4FBF-BB99-F460AD54A6E5Q35083682-7C0A942E-516C-4CC7-95D7-9BC979A8C805Q35161614-055766AB-48AF-449D-B6AF-4CDCDCBF6F33Q35376007-261A7E71-C2F8-4F4B-9231-05F44E1D10BDQ35846436-682E3DBA-EEF0-4A80-881E-BBDC8AC5F2ECQ35869605-9E36C1D8-1F01-4354-AA6D-065BDB25AD56Q35877773-94DA09F0-B6B2-4BEC-90DC-6B6C0962D2F2Q35930922-D4D641AA-C1DC-4876-A51C-649D69B967CDQ36078316-65514791-A6A2-49CC-8CB5-C331BF4C7A7BQ36111393-2FDBD97E-A46D-4942-A8C9-F8D96D61AA0EQ36283755-5CE6268B-CC97-4686-B81D-A66DFCAAC73BQ36647979-665CCAD6-D439-41DD-93CA-360837B232B4Q36984883-939F707B-5047-416B-B4AA-53DC49A94A4EQ37014160-84F1C4EC-7104-42A5-8E63-24478BE4DD58Q37109212-08D4E252-AA8E-456E-9936-44563EE1FC6BQ37124032-EE0FB11D-61F1-4643-B9DA-5DB087E0D247Q37297999-AF8F97C6-83E9-4712-8B5C-1298B393316CQ37550108-AFD8AC16-AB75-4A4B-8763-017F939A728CQ37588248-04AA4197-8FF5-44EE-8DF6-0116A82CC1FDQ37633859-592D93AF-0B82-4B64-B608-DD95A145E26EQ37680481-A8F1A658-FCF6-4777-8235-3BFCAB5C6BFFQ37696597-560E9DFE-BA19-4690-BE3F-0B59F05A233AQ38080794-1DC12136-B4D1-4F58-A4DD-3A01F932521BQ38139812-7E1FF45F-890D-487D-9439-CDE8E6F7C974Q38153607-0F716753-403A-46FF-AFA7-7D91DD0BD839Q38235232-4C63A690-B258-4661-B1F0-71C4AEBF6E0BQ38538221-C032D448-92DB-41D5-91BD-FD18FFDC3AF5Q38600142-EDA00F14-59AF-417E-9B7F-7CE569A903B3Q38739354-7B31FFE6-0D76-4F34-BF37-C26871430CD7Q38746746-8081E3E2-9EB7-4AE1-B0A3-486ECDA6F353Q38792836-92115427-641C-4628-8CAA-C4B406D19537Q38904050-7792931E-637E-4D30-A577-751BEEC63B98
P2860
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Fidaxomicin versus vancomycin ...... randomized controlled trials.
@en
type
label
Fidaxomicin versus vancomycin ...... randomized controlled trials.
@en
prefLabel
Fidaxomicin versus vancomycin ...... randomized controlled trials.
@en
P2093
P2860
P356
P1476
Fidaxomicin versus vancomycin ...... l randomized controlled trials
@en
P2093
A Sarah Walker
Bernadette C Young
Derrick W Crook
Karl Weiss
Mark A Miller
Nicole E Stoesser
Roberto Esposito
Sherwood L Gorbach
Study 003/004 Teams
Thomas J Louie
P2860
P304
P356
10.1093/CID/CIS499
P407
P478
55 Suppl 2
P577
2012-08-01T00:00:00Z